Research on the Treatment of Dry AMD

Photobiomodulation is a dynamic field of research. Stay up-to-date on clinical trials and therapeutic advances.

The Current Research Landscape

The development of new therapies is a long, complex process. Here you can see the current stages of the most promising approaches for treating dry AMD.

Our Research Pipeline

An overview of the current status of the therapeutic approaches we are pursuing.

Exploration4/5

Initial laboratory studies and preclinical tests

Early Trial Phase5/5

First studies in patients (Phase I/II)

Advanced Trials5/5

Large clinical trials (Phase III)

Approved3/5

Officially approved and available

For a detailed, evidence-based overview of treatment options for dry AMD, we recommend the resource page trockene-amd-behandeln.net.

Latest from Research and Media

Stay informed about the latest developments, publications, and regulatory decisions in AMD therapy.

Award

Healthy Hub 2025: MACULIGHT honored

SBK / mhplus, July 2025

MACULIGHT by Ciromed was honored as one of five health innovations in the Healthy Hub 2025 competition – supported by BIG direkt gesund and mhplus.

Press Release

Launch of the MACULIGHT Study

Press Release, September 2025

The BMFTR-funded MACULIGHT® study on the treatment of dry AMD with photobiomodulation using a home device has officially started at five German study centers.

Regulatory

FDA authorizes light therapy for dAMD

AAO, January 2025

The FDA has authorized a non-invasive light therapy (photobiomodulation) for the treatment of dry AMD and geographic atrophy for the first time.

Research

New eye drops for dry AMD

Pro Retina, January 2025

A South Korean research team has developed a medication in the form of eye drops for treating dry AMD – another innovative therapeutic approach.

Stay Informed About Study Progress

Register now to receive the latest information on study results, new therapy options, and participating centers near you.